September 2015 - Monthly Update, Quest Diagnostics Nichols Institute, Valencia

NEW TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated.			
Test Code	**Test Name**	**Effective Date**	**Page #**
93103	**Insulin, Intact, LC/MS/MS**	10/12/2015	2
92063	**Cardio IQ® Diabetes and ASCVD Risk Panel with Scores**	10/26/2015	2
19688X	**HPV (Human Papillomavirus), Low and High Risk DNA, ISH**	10/26/2015	4
16184X	**MPL W515 and MPL S505 Mutation Analysis, Qualitative, Leumeta®**	10/26/2015	4

TEST CHANGES Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated.				
Test Code	**Former Test Code**	**Test Name**	**Effective Date**	**Page #**
613	4871	Lithium	10/5/2015	5
92208		3a-Androstanediol Glucuronide, ELISA	10/12/2015	6
3481	4870R	Copper, RBC	10/12/2015	6
91083		**Insulin, B-chain, LC/MS/MS**	10/12/2015	6
6354	4877R	Zinc, RBC	10/12/2015	7
30958	4912U	Alprazolam, Quantitative, Urine	10/19/2015	7
15975	4093U	**Benzodiazepines, Expanded, Quantitative, Urine**	10/19/2015	8
90264	4090U	Benzodiazepines, Quantitative, Urine	10/19/2015	8
40064	4939U	Clonazepam and 7-amino Clonazepam, Urine	10/19/2015	9
11196	9189	Cryptococcal Antigen, Latex Screen with Reflex to Titer	10/19/2015	9
11290	S51000	Fecal Globin by Immunochemistry	10/19/2015	10
90924		**Hepatitis C Viral RNA NS3 Drug Resistance**	10/26/2015	10
4165		Minerals Analysis RBC w/K+	10/26/2015	11
17183	A52223	Progesterone, LC/MS/MS	10/26/2015	11
90473		RET/PTC Rearrangement, Thyroid Cancer	10/26/2015	11
36598		T3, Free, Tracer Dialysis	10/26/2015	12

DISCONTINUED TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated.			
Test Code	**Test Name**	**Effective Date**	**Page #**
795	Antibody Screen, RBC with Reflex to Identification, Titer, and Antigen Typing	10/5/2015	12
91432	HIV-1/2 Antibody Differentiation (Supplemental Use Only)	10/5/2015	12
91778	HIV-1/2 Antibody Differentiation (Supplemental Use Only) with Reflex to HIV-1 RNA, TMA	10/5/2015	12
S48967	RBC Antibody Identification	10/5/2015	12

New Test Offerings

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party.
Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.

The following tests will be available through Quest Diagnostics on the dates indicated below.

Insulin, Intact, LC/MS/MS	
Effective Date	**10/12/2015**
Test Code	**93103**
CPT Codes	**83525**
Specimen Requirements	**0.5 mL (0.3 mL minimum) serum**
Reject Criteria	**Hemolysis**
Instructions	**Overnight fasting is required.** **Collect blood samples observing routine precautions for venipuncture. Allow serum samples to clot completely before centrifugation.**
Transport Temperature	**Refrigerated**
Specimen Stability	**Room temperature: 24 hours** **Refrigerated: 28 days** **Frozen: 56 days**
Set-up/Analytic Time	**Set up: Tue, Thurs; Report available: 3-8 days**
Reference Range	**< or = 16 uIU/mL**
Methodology	**Immunocapture Liquid Chromatography/Tandem Mass Spectrometry**
Performing Site	**Quest Diagnostics Nichols Institute, San Juan Capistrano**
Interface Mapping	**Result Code** / **Result Name** **86013595** / **Insulin, Intact, LC/MS/MS**

Cardio IQ® Diabetes and ASCVD Risk Panel with Scores	
Clinical Significance	**The increasing prevalence of obesity has led to an epidemic of diabetes mellitus and related complications, including ASCVD. Prediction of the risk of ASCVD and of developing diabetes in the Cardio IQ® lab report will simplify and improve the communication of those risks to patients.** **This panel provides the 10-year and lifetime risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomophic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting Pharmacology or lifestyle interventions.**
Effective Date	**10/26/2015**
Test Code	**92063**
CPT Codes	**82947, 83036, 82465, 83718, 84478**
Specimen Requirements	**4 mL (2 mL minimum) serum collected in a serum separator tube AND 1 mL (0.5 mL minimum) whole blood collected an EDTA (lavender-top) tube**
Reject Criteria	**Red-top tube (no gel); gross hemolysis; moderate to grossly icteric; sodium fluoride/oxalate (grey-top) tube; heparinized plasma**
Instructions	**For risk calculations to be performed, the following patient-specific information must be provided at the time of order:** **Age: Years** **Gender: M (for male) or F (for female)** **Height Feet: Feet**

	Height Inches: Inches **Weight: lbs** **Race - African American: Y (for yes) or N (for no)** **Systolic Blood Pressure: mmHg** **Diastolic Blood Pressure: mmHg** **Treatment for High B.P.: Y (for yes) or N (for no)** **Diabetes Status: Y (for yes) or N (for no)** **Parental History of Diab: Y (for yes) or N (for no)** **Smoking Status: Y (for yes) or N (for no)** **Patient should fast 9-12 hours prior to collection.** **The assay manufacturer Beckman Coulter advises: "N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been...determined to interfere with assays for...Cholesterol, Uric Acid" where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hr, a second dose of 50 mg/kg administered over 4 hrs and a third dose of 100 mg/kg administered over 16 hrs.**
Transport Temperature	**Refrigerated**
Specimen Stability	**Serum:** **Room temperature: 48 hours** **Refrigerated: 5 days** **Frozen: 15 days** **Whole blood:** **Room temperature and Refrigerated: 7 days** **Frozen: 6 months**
Set-up/Analytic Time	**Set up: Mon-Fri; Report available: 3-6 days**
Reference Range	**Accompanies report**
Methodology	**Spectrophotometry, Immunoturbidimetry, Enzymatic**
Performing Site	**Quest Diagnostics Nichols Institute, San Juan Capistrano**
Interface Mapping	

Result Code	Type	Result Name	Unit of Measure
25000000		Glucose	mg/dL
50026400		Hemoglobin A1c	
25003000		Cholesterol, Total	mg/dL
25015900		HDL Cholesterol	mg/dL
25002900		Triglycerides	mg/dL
25016900		LDL Chol, Calculated	mg/dL
25017000		Cholesterol/HDL Ratio	calc
25017210		Non-HDL Cholesterol	mg/dL
86010626		10 Year ASCVD Risk	%
86010627		10 Year ASCVD Risk Goal	%
86010628		Lifetime ASCVD Risk	%
86010499		8 Year Diabetes Risk	%
25025800	Prompt-Result	Height Feet	ft
25026300	Prompt-Result	Height Inches	in
85997769	Prompt-Result	Weight	lbs
86010502		Calculated BMI	
86010629	Prompt-Result	African American	

86006867	Prompt-Result	Systolic Blood Pressure	mmHg
86010657	Prompt-Result	Diastolic Blood Pressure	mmHg
86010497	Prompt-Result	Treatment for High B.P.	
86006870	Prompt-Result	Diabetes	
86010658	Prompt-Result	Parental History of Diab	
86006866	Prompt-Result	Current Smoker	

This is a true reflex. Please build the unit code below separately.
Non-orderable test code 92063-7-Cardio IQ(R) Direct LDL

Result Code		Result Name	Unit of Measure
25008600		Direct LDL	mg/dL

Additional Information	**If Triglyceride is >400 mg/dL, then Cardio IQ® Direct LDL will be performed at an additional charge (CPT code 83721).**

HPV (Human Papillomavirus), Low and High Risk DNA, ISH	
Clinical Significance	**HPV is the causative agent of cervical dysplasia and carcinoma. Selected low-risk and high-risk subtypes are assessed in tissue block.**
Effective Date	**10/26/2015**
Test Code	**19688X**
CPT Codes	**88365, 88364**
Specimen Requirements	**Formalin fixed paraffin embedded tissue collected in an IHC specimen transport kit**
Instructions	**Do not place labels with adhesive backing on slides. Use pencil or xylene-resistant pen to write on the frosted end of the slide only.**
Transport Temperature	**Room temperature**
Specimen Stability	**Room temperature and Refrigerated: Indefinite** **Frozen and -70 Degrees: Do Not Freeze**
Set-up/Analytic Time	**Set up: Mon-Sat; Report available: 2-5 days**
Methodology	**In-Situ Hybridization**
Performing Site	**Quest Diagnostics Nichols Institute, San Juan Capistrano**

Interface Mapping

Result Code	Type	Result Name
21081	Prompt-Result	PRIMARY BIOPSY SITE:
22186	Prompt-Result	PARAFFIN BLOCK NUMBER:
27109		QUEST INTERNAL NUMBER:
30232		HPV High Risk
30233		HPV Low Risk
30234		DNA Detected

MPL W515 and MPL S505 Mutation Analysis, Qualitative, Leumeta®	
Clinical Significance	**Diagnose sporadic and familial chronic myeloproliferative diseases (polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis) in patients with a negative JAK2 test result.**

Effective Date	**10/26/2015**
Test Code	**16184X**
CPT Codes	**81402**
Specimen Requirements	**Preferred:** **6 mL (3 mL minimum) whole blood collected in an EDTA preservative tube** **Acceptable:** **3 mL (2 mL minimum) bone marrow collected in an EDTA preservative tube**
Transport Temperature	**Refrigerated**
Specimen Stability	**Room temperature and Refrigerated: 72 hours** **Frozen: Unacceptable**
Set-up/Analytic Time	**Set up: Tues-Sat; Reports in 3-4 days**
Reference Range	**Not detected**
Methodology	**Polymerase Chain Reaction and bidirectional Sequencing**
Performing Site	**Quest Diagnostics Nichols Institute, San Juan Capistrano**
Interface Mapping	**Result Code** / **Result Name** **16184** / **MPL W515 Mutation** **31124** / **MPL S505 Mutation**

Test Changes

The following test changes will be effective on the dates indicated below. **Please note information that is changing appears in bold text in this update.** *Former test names and test codes have been italicized*.

Lithium	
Clinical Significance	**Lithium is used to treat manic-depressive disorders and the manic phase of affective disorders, including mania. The therapeutic window is relatively small. Therapeutic drug monitoring is useful to optimize dose and avoid toxicity.**
Effective Date	**10/5/2015**
Former Test Code	*4871*
Test Code	**613**
Specimen Requirements	**2 mL** (0.5 mL minimum) serum
Reject Criteria	**Plasma from lithium-based anticoagulants**
Instructions	**Collect just prior to next dose**
Transport Temperature	**Room temperature**
Specimen Stability	**Room temperature and Refrigerated: 10 days** **Frozen: Not Established**
Performing Site	Quest Diagnostics Nichols Institute, Valencia
Interface Mapping	**Result Code** / **Result Name** **80013600** / Lithium

Pricing Message	Negotiated pricing on 4871 will be applied to code 613.

3a-Androstanediol Glucuronide, ELISA	
Message	****This test is now available for New York patient testing*****
Effective Date	**10/12/2015**
Test Code	92208
Instructions	**Fasting is preferred**
Transport Temperature	**Refrigerated**
Performing Site	Quest Diagnostics Nichols Institute, San Juan Capistrano

Copper, RBC	
Message	***This test is not available for New York patient testing***
Clinical Significance	**Copper is an essential element that is a cofactor of many enzymes. Copper metabolism is disturbed in Wilson's disease, Menkes disease, primary biliary cirrhosis, and Indian childhood cirrhosis. Copper concentrations increase in acute phase reactions. Copper concentrations are decreased with nephrosis, malabsorption, and malnutrition. Copper concentrations are also useful to monitor patients, especially preterm newborns, on nutritional supplementation. Results of copper are often interpreted together with ceruloplasmin.**
Effective Date	**10/12/2015**
Former Test Code	*4870R*
Test Code	3481
Specimen Requirements	**Preferred:** **0.5 mL (0.3 mL minimum) red blood cells collected in an EDTA (royal blue-top) tube** **Acceptable:** **Red blood cells collected in an EDTA (lavender-top), sodium heparin trace-metal (royal blue-top), sodium heparin (green-top) sodium heparin lead-free (tan-top) or lithium heparin (green-top) tube**
Instructions	Carefully clean skin prior to venipuncture. Avoid hemolysis. Avoid worksite collection. **Red blood cells Trace Metal** **Use the royal blue-top trace metal evacuated tube (Becton-Dickinson catalog# 367736) with EDTA for RBC trace metal testing.** **Centrifuge and separate RBCs into an acid washed plastic screw cap vial within two hours of collection.**
Performing Site	Quest Diagnostics Nichols Institute, Valencia
Interface Mapping	**Result Code** / **Result Name** / **Unit of Measure** **85984230** / Copper, RBC / mg/L
Pricing Message	Negotiated pricing on 4870R will be applied to code 3481.

Insulin, B-chain, LC/MS/MS	
Effective Date	**10/12/2015**
Former Test Name	*Insulin, LC/MS/MS*
Test Code	91083
Specimen Requirements	**0.5 mL (0.4 mL minimum)** frozen serum collected in a red-top tube (no gel)
Set-up/Analytic Time	**Set up: Tues, Thurs; Report available: 2-7 days**

Performing Site	Quest Diagnostics Nichols Institute, San Juan Capistrano

Zinc, RBC	
Message	***This test is not available for New York patient testing***
Clinical Significance	**Zinc is an essential element involved in a myriad of enzyme systems including wound healing, immune function, and fetal development. Zinc measurements are used to detect and monitor industrial, dietary, and accidental exposure to zinc. Also, zinc measurements may be used to evaluate health and monitor response to treatment.**
Effective Date	**10/12/2015**
Former Test Code	*4877R*
Test Code	6354
Specimen Requirements	**Preferred:** **0.5 mL (0.3 mL minimum) red blood cells collected in an EDTA (royal blue-top) tube** **Acceptable:** **Red blood cells collected in an EDTA (lavender-top), sodium heparin trace-metal (royal blue-top), sodium heparin (green-top), sodium heparin lead-free (tan-top) or lithium heparin (green-top) tube**
Instructions	**Carefully clean skin prior to venipuncture.** **Avoid hemolysis.** **Avoid worksite collection.** **Red blood cells Trace Metal** **Use the royal blue-top trace metal evacuated tube (Becton-Dickinson catalog# 367736) with EDTA for RBC trace metal testing.** **Centrifuge and separate RBCs into an acid washed plastic screw cap vial within two hours of collection.**
Performing Site	Quest Diagnostics Nichols Institute, Valencia
Interface Mapping	**Result Code** / **Result Name** / **Unit of Measure** **85992436** / **Zinc, RBC** / mg/L
Pricing Message	Negotiated pricing on 4877R will be applied to code 6354.

Alprazolam, Quantitative, Urine	
Effective Date	**10/19/2015**
Former Test Code	*4912U*
Test Code	**30958**
CPT Codes	**80346 (HCPCS: G6031)**
Specimen Requirements	7 mL (2 mL minimum) random urine **collected in a sterile, leak-proof container**
Reject Criteria	**Preserved specimens**
Instructions	**Collect random urine, no preservative**
Performing Site	Quest Diagnostics Nichols Institute, Valencia
Interface Mapping	**Result Code** / **Result Name** / **Unit of Measure** **86007287** / Alprazolam / ng/mL **86007288** / Hydroxyalprazolam / ng/mL
Pricing Message	Negotiated pricing on 4912U will be applied to code 30958.

<table>
<tr><th colspan="2">Benzodiazepines, Expanded, Quantitative, Urine</th></tr>
<tr><td>Clinical Significance</td><td>This test is utilized to monitor compliance with prescribed drug therapy.</td></tr>
<tr><td>Effective Date</td><td>10/19/2015</td></tr>
<tr><td>Former Test Name</td><td>Benzodiazepine Expanded, Quant, Urine</td></tr>
<tr><td>Former Test Code</td><td>4093U</td></tr>
<tr><td>Test Code</td><td>15975</td></tr>
<tr><td>CPT Codes</td><td>80346 (HCPCS: G6031)</td></tr>
<tr><td>Specimen Requirements</td><td>20 mL (5 mL minimum) urine collected in a sterile, leak-proof container</td></tr>
<tr><td>Performing Site</td><td>Quest Diagnostics Nichols Institute, Valencia</td></tr>
<tr><td>Interface Mapping</td><td>
<table>
<tr><th>Result Code</th><th>Result Name</th><th>Unit of Measure</th></tr>
<tr><td>86007188</td><td>Clonazepam</td><td>ng/mL</td></tr>
<tr><td>86007189</td><td>7-Amino clonazepam</td><td>ng/mL</td></tr>
<tr><td>86007190</td><td>Alpha hydroxyalprazolam</td><td>ng/mL</td></tr>
<tr><td>86007191</td><td>Alpha hydroxytriazolam</td><td>ng/mL</td></tr>
<tr><td>86007192</td><td>Alprazolam</td><td>ng/mL</td></tr>
<tr><td>86007193</td><td>Lorazepam</td><td>ng/mL</td></tr>
<tr><td>86007195</td><td>Norchlordiazepoxide</td><td>ng/mL</td></tr>
<tr><td>86007196</td><td>Nordiazepam</td><td>ng/mL</td></tr>
<tr><td>86007198</td><td>Oxazepam</td><td>ng/mL</td></tr>
<tr><td>86007199</td><td>Temazepam</td><td>ng/mL</td></tr>
<tr><td>86010828</td><td>Triazolam</td><td>ng/mL</td></tr>
<tr><td>86013426</td><td>Alpha hydroxymidazolam</td><td>ng/mL</td></tr>
<tr><td>86013427</td><td>Hydroxyethylflurazepam</td><td>ng/mL</td></tr>
</table>
</td></tr>
<tr><td>Additional Information</td><td>Result codes 210375 for Midazolam and 210714 for Desalkylflurazepam will be removed.</td></tr>
<tr><td>Pricing Message</td><td>Negotiated pricing on 4093U will be applied to code 15975.</td></tr>
</table>

<table>
<tr><th colspan="2">Benzodiazepines, Quantitative, Urine</th></tr>
<tr><td>Clinical Significance</td><td>Confirmation of screen positive results. This panel contains the following 11 analytes: Alpha-Hydroxyalprazolam, Alpha-Hydroxytriazolam, Alprazolam, Lorazepam, Alpha-Hydroxymidazolam, Norchlordiazepoxide, Nordiazepam, Hydroxyethylflurazepam, Oxazepam, Temazepam, Triazolam.</td></tr>
<tr><td>Effective Date</td><td>10/19/2015</td></tr>
<tr><td>Former Test Code</td><td>4090U</td></tr>
<tr><td>Test Code</td><td>90264</td></tr>
<tr><td>Transport Temperature</td><td>Room temperature</td></tr>
<tr><td>Specimen Stability</td><td>Room temperature: 7 days
Refrigerated and Frozen: 14 days</td></tr>
<tr><td>Set-up/Analytic Time</td><td>Set up: Tues, Thurs, Sat; Report available: 2-8 days</td></tr>
<tr><td>Performing Site</td><td>Quest Diagnostics Nichols Institute, Valencia</td></tr>
</table>

Interface Mapping	

Result Code	Result Name	Unit of Measure
86007322	Alpha-Hydroxyalprazolam	ng/mL
86007323	Alpha-Hydroxytriazolam	ng/mL
86007324	Alprazolam	ng/mL
86007325	Lorazepam	ng/mL
86013426	**Alpha-Hydroxymidazolam**	ng/mL
86007327	Norchlordiazepoxide	ng/mL
86007328	Nordiazepam	ng/mL
86013427	**Hydroxyethylflurazepam**	ng/mL
86007330	Oxazepam	ng/mL
86007331	Temazepam	ng/mL
86007332	Triazolam	ng/mL

Additional Information	**Result codes 210375 Midazolam and 210714 Desalkylflurazepam will be removed.**
Pricing Message	Negotiated pricing on 4090U will be applied to code 90264.

Clonazepam and 7-amino Clonazepam, Urine	
Clinical Significance	**Clonazepam (Klonopin) belongs to a group of drugs called benzodiazepines. Benzodiazepines are sedative-hypnotic drugs that help to relieve nervousness, tension, anxiety symptoms, and seizures by slowing the central nervous system.**
Effective Date	**10/19/2015**
Former Test Code	*4939U*
Test Code	**40064**
Transport Temperature	**Refrigerated**
Performing Site	Quest Diagnostics Nichols Institute, Valencia
Interface Mapping	

Result Code	Result Name	Unit of Measure
86003160	Clonazepam	ng/mL
86003162	7-amino Clonazepam	ng/mL

Pricing Message	Negotiated pricing on 4939U will be applied to code 40064.

Cryptococcal Antigen, Latex Screen with Reflex to Titer	
Effective Date	**10/19/2015**
Former Test Code	*9189*
Test Code	**11196**
Performing Site	**This test performed at Focus Diagnostics, Inc. will also be performed at Quest Diagnostics Nichols Institute, Valencia**
Pricing Message	Negotiated pricing on 9189 will be applied to code 11196

Fecal Globin by Immunochemistry	
Message	*****This test is now available for New York patient testing at SJC.*****
Clinical Significance	**The fecal occult blood test is an immunochromatographic fecal occult blood test that qualitatively detects human hemoglobin from blood in fecal samples. This is a useful screening aid for detecting primarily lower gastrointestinal (G.I.) disorders that may be related to iron deficiency anemia, diverticulitis, ulcerative colitis, polyps, adenomas, colorectal cancers or other G.I. lesions that can bleed. It is recommended for use by health professionals as part of routine physical examinations and in screening for colorectal cancer or other sources of lower G.I. bleeding.**
Effective Date	**10/19/2015**
Former Test Code	*S51000*
Test Code	**11290**
Specimen Requirements	**Fecal specimen (minimum one Insure™ FOBT test card with specimen applied to one window) collected from toilet water and brushed on the InSure™ FOBT test card**
Reject Criteria	**Stool submitted in any container; InSure™ FOBT cards with stool applied to the sample windows; any test card with obvious blood present**
Instructions	**No special diet or avoidance of drugs or supplements is required for the InSure™ test.** **Fecal specimen must be collected from toilet water and brushed on the InSure™ FOBT Test Card. Protect from direct sunlight. For clarification of collection instructions, please contact Customer Support at 1-800-642-4657.**
Set-up/Analytic Time	Set up: Mon-Fri; **Report available: 1-4 days**
Performing Site	**This test performed at Quest Diagnostics, West Hills will also be performed at Quest Diagnostics Nichols Institute, San Juan Capistrano**
Interface Mapping	**Result Code** / **Result Name** **86002176** / **Fecal Globin**
Additional Information	**Result code 107971 for Source, 107969 for Micro Number, 107970 for Test Status, and 107972 for Specimen Comments will be removed.**
Pricing Message	Negotiated pricing on S51000 will be applied to code 11290.

Hepatitis C Viral RNA NS3 Drug Resistance	
Clinical Significance	**This assay may be used to detect boceprevir, simeprevir and paritaprevir resistance-associated NS3 mutations in NS3 protease inhibitor treatment-experienced patients and also the Q80K polymorphism in patients being considered for a simeprevir-containing regimen.**
Effective Date	**10/26/2015**
Former Test Name	*Hepatitis C Viral RNA NS3 Genotype*
Test Code	90924
Reference Range	HCV NS3 Subtype: Not detected Boceprevir Resistance: Not predicted **Paritaprevir Resistance: Not predicted** Simeprevir Resistance: **Not predicted**
Performing Site	Focus Diagnostics, Inc.
Interface Mapping	**Result Code** / **Result Name** 86008373 / HCV NS3 Subtype 86008374 / Boceprevir Resistance **86013796** / **Paritaprevir Resistance**

	86010353 | Simeprevir Resistance
Additional Information	**Result code 86008375 - Telaprevir will be removed.**

Minerals Analysis RBC w/K+	
Effective Date	**10/26/2015**
Test Code	4165
Specimen Requirements	3 mL (2 mL minimum) whole blood collected in an EDTA (royal blue-top) tube tube **AND 0.5 mL (0.3 mL minimum) RBC collected in an EDTA (royal blue-top) tube**
Performing Site	Quest Diagnostics Nichols Institute, Valencia

Progesterone, LC/MS/MS	
Effective Date	**10/26/2015**
Former Test Code	*A52223*
Test Code	**17183**
Reject Criteria	**Samples collected in SST tubes**
Set-up/Analytic Time	Set up: Sun-Fri; **Report available: 2-5 days**
Reference Range	Pediatric Reference Ranges for Progesterone, LC/MS/MS: Males: 5-9 years: < or = 0.7 ng/mL 10-13 years: < or = 1.2 ng/mL 14-17 years: < or = 0.8 ng/mL Females: 5-9 years: < or = 0.6 ng/mL 10-13 years: < or = 10.2 ng/mL 14-17 years: < or = 11.9 ng/mL **Adult Reference Ranges for Progesterone, LC/MS/MS:** Males: 18-29 years: < or = 0.3 ng/mL 30-39 years: < or = 0.2 ng/mL 40-49 years: < or = 0.2 ng/mL 50-59 years: < or = 0.2 ng/mL **Females:** **Follicular Phase: < or = 2.7 ng/mL** **Luteal Phase: 3.0-31.4 ng/mL** **Postmenopausal Phase: < or = 0.2 ng/mL**
Performing Site	Quest Diagnostics Nichols Institute, San Juan Capistrano
Interface Mapping	**Result Code** | **Result Name** **86000327** | Progesterone, LC/MS/MS
Pricing Message	Negotiated pricing on A52223 will be applied to code 17183

RET/PTC Rearrangement, Thyroid Cancer	
Effective Date	**10/26/2015**
Test Code	90473
Specimen Stability	**Room temperature and Refrigerated: Indefinite** **Frozen: Do Not Freeze**

Performing Site	Quest Diagnostics Nichols Institute, San Juan Capistrano

T3, Free, Tracer Dialysis	
Effective Date	**10/26/2015**
Test Code	36598
Reference Range	**Free T3:** Adult Reference Range for T3, Free, Tracer Dialysis: 210-440 pg/dL **Pregnancy Reference Ranges for Free T3: 200-380 pg/dL (all trimesters)** Pediatric Reference Range for T3, Free, Tracer Dialysis: 1-9 years: 282-518 pg/dL 10-13 years: 286-556 pg/dL 14-17 years: 242-501 pg/dL **T3, Total:** **<4 years: Reference Range Not Established** 4-9 years: 104-190 ng/dL 10-13 years: 94-213 ng/dL 14-17 years: 84-179 ng/dL > or = 18 years: 76-181 ng/dL
Performing Site	Quest Diagnostics Nichols Institute, San Juan Capistrano

Discontinued Tests

Antibody Screen, RBC with Reflex to Identification, Titer, and Antigen Typing	
Effective Date	**10/5/2015**
Test Code	795
Additional Information	There is no recommended alternative.

HIV-1/2 Antibody Differentiation (Supplemental Use Only)	
Effective Date	**10/5/2015**
Test Code	91432
Additional Information	The standalone HIV-1/2 Antibody Differentiation assay (i.e., Multispot Test"), is being discontinued in order to comply with the current CDC HIV Diagnostic recommended testing algorithm (June 27, 2014). That algorithm specifies that the first HIV diagnostic test should be a highly sensitive HIV-1/2 Antigen/Antibody screening assay (Quest Diagnostics Test Code 91431 - HIV 1/2 Antigen and Antibodies, Fourth Generation, with Reflexes). Please consult the CDC recommendations document-- www.cdc.gov/hiv/pdf/hivtestingalgorithmrecommendation-final.pdf for more information.

HIV-1/2 Antibody Differentiation (Supplemental Use Only) with Reflex to HIV-1 RNA, TMA	
Effective Date	**10/5/2015**
Test Code	91778
Additional Information	The standalone HIV-1/2 Antibody Differentiation assay (i.e., "Multispot Test"), is being discontinued in order to comply with the current CDC HIV Diagnostic recommended testing algorithm (June 27, 2014). That algorithm specifies that the first HIV diagnostic test should be a highly sensitive HIV-1/2 Antigen/Antibody screening assay (Quest Diagnostics Test Code 91431 - HIV 1/2 Antigen and Antibodies, Fourth Generation, with Reflexes). Please consult the CDC recommendations document-- www.cdc.gov/hiv/pdf/hivtestingalgorithmrecommendation-final.pdf for more information.

RBC Antibody Identification	
Effective Date	**10/5/2015**
Test Code	S48967

Additional Information	There is no recommended alternative.

Quest, Quest Diagnostics, the associated logo, Nichols Institute and all associated
Quest Diagnostics marks are the trademarks of Quest Diagnostics. ©2015 Quest Diagnostics Incorporated. All rights reserved. www.questdiagnostics.com